Polypid Ltd (PYPD) Stock Price, Quote & News

Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 7 4719 5700

Website: www.polypid.com

Address:

18 Hasivim Street, Petah Tikva, Israel

Finnish_boy Oct. 21 at 7:58 AM

$PYPD https://www.clinicalleader.com/doc/how-one-biopharma-company-overcame-trial-failure-0001

0 · Reply

Finnish_boy Oct. 21 at 7:51 AM

$PYPD Bought this.. dirty cheap.. there are some risks but this is exceptionally "risk-free" bio. GLP1-massive potential bonus for $55M market cap company: "I expect that this program, once we have this more robust preclinical data, will be a subject to some sort of a collaboration." And stock is too cheap considering only D-PLEX_100

0 · Reply

WallStWireAds Oct. 12 at 3:39 PM

$PYPD https://thefinanceherald.com/an-overlooked-crisis-in-hospitals-could-be-pharmas-next-great-opportunity/

0 · Reply

CARTE_BLANCHE_DEVEREAUX Oct. 9 at 9:35 PM

$PYPD Easy to accumulate until mid Q1. Not expecting any fireworks til mid 26. I'm super happy at these levels.

1 · Reply

PaulWalter Oct. 9 at 8:54 AM

$PYPD It seems they can‘t get a deal/ partnership over the line. Product should sell itself.

1 · Reply

PaulWalter Oct. 8 at 4:57 PM

$PYPD This is the most boring stock in history.

1 · Reply

Nigoolas Oct. 8 at 3:30 AM

$PYPD very nice entry atm!! BEST stock ever!!

0 · Reply

Stef_DL Oct. 7 at 7:59 PM

$PYPD A temping buy whenever she dips closer to 3. I might need to step in for a little buying 😊.

0 · Reply

NVDAMillionaire Oct. 2 at 6:15 AM

$PYPD Great piece that accurately captures PYPD's current position. So if you want to refresh your understanding of PYPD or learn about PYPD for the first time, this is essential reading. https://beyondspx.com/quote/PYPD/analysis/polypid-s-d-plex100-a-breakthrough-in-surgical-infection-prevention-poised-for-market-entry-pypd

0 · Reply

BenGang Oct. 1 at 3:12 PM

$PYPD

0 · Reply

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

Sep 17, 2025, 8:44 AM EDT - 5 weeks ago

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

Sep 16, 2025, 8:30 AM EDT - 5 weeks ago

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

Sep 3, 2025, 8:30 AM EDT - 7 weeks ago

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 2, 2025, 8:30 AM EDT - 7 weeks ago

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

Aug 13, 2025, 4:52 PM EDT - 2 months ago

PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:30 AM EDT - 2 months ago

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 8:00 AM EDT - 2 months ago

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

Jul 30, 2025, 8:00 AM EDT - 3 months ago

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

Jul 15, 2025, 8:00 AM EDT - 3 months ago

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

Jun 16, 2025, 7:20 PM EDT - 4 months ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

Jun 11, 2025, 9:42 AM EDT - 4 months ago

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:40 AM EDT - 4 months ago

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 9, 2025, 8:54 AM EDT - 4 months ago

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

Jun 9, 2025, 7:30 AM EDT - 4 months ago

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

Jun 6, 2025, 4:05 PM EDT - 5 months ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

May 30, 2025, 10:12 AM EDT - 5 months ago

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

May 20, 2025, 7:00 AM EDT - 5 months ago

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 14, 2025, 1:24 PM EDT - 5 months ago

PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:00 AM EDT - 5 months ago

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 7:00 AM EDT - 6 months ago

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

Apr 22, 2025, 7:00 AM EDT - 6 months ago

PolyPid to Participate in The Citizens Life Sciences Conference

Mar 11, 2025, 7:00 AM EDT - 8 months ago

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Mar 3, 2025, 7:00 AM EST - 8 months ago

PolyPid to Participate in the 37th Annual ROTH Conference

Feb 12, 2025, 10:44 AM EST - 9 months ago

PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 7:00 AM EST - 9 months ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Jan 30, 2025, 7:00 AM EST - 9 months ago

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 29, 2025, 7:00 AM EST - 9 months ago

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Dec 26, 2024, 10:31 AM EST - 10 months ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA AVXL

Dec 23, 2024, 7:22 PM EST - 10 months ago

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

Dec 11, 2024, 7:00 AM EST - 11 months ago

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

Nov 29, 2024, 1:05 PM EST - 11 months ago

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Nov 13, 2024, 2:06 PM EST - 1 year ago

PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

Oct 30, 2024, 8:00 AM EDT - 1 year ago

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

Oct 21, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Oct 1, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Sep 3, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Participate in Three Upcoming Fall Investor Conferences

Aug 14, 2024, 1:25 PM EDT - 1 year ago

PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 8:31 PM EDT - 1 year ago

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

Jul 31, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024

Jun 10, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial

May 9, 2024, 10:38 PM EDT - 1 year ago

PolyPid Ltd (PYPD) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:00 AM EDT - 1 year ago

PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 1, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Participate in Citizens JMP Life Sciences Conference

Apr 30, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Apr 24, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024

Feb 28, 2024, 7:00 AM EST - 1 year ago

PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

Feb 14, 2024, 11:13 AM EST - 1 year ago

PolyPid Ltd (PYPD) Q4 2023 Earnings Call Transcript

Feb 14, 2024, 7:00 AM EST - 1 year ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Finnish_boy Oct. 21 at 7:58 AM

$PYPD https://www.clinicalleader.com/doc/how-one-biopharma-company-overcame-trial-failure-0001

0 · Reply

Finnish_boy Oct. 21 at 7:51 AM

0 · Reply

WallStWireAds Oct. 12 at 3:39 PM

$PYPD https://thefinanceherald.com/an-overlooked-crisis-in-hospitals-could-be-pharmas-next-great-opportunity/

0 · Reply

CARTE_BLANCHE_DEVEREAUX Oct. 9 at 9:35 PM

$PYPD Easy to accumulate until mid Q1. Not expecting any fireworks til mid 26. I'm super happy at these levels.

1 · Reply

PaulWalter Oct. 9 at 8:54 AM

$PYPD It seems they can‘t get a deal/ partnership over the line. Product should sell itself.

1 · Reply

PaulWalter Oct. 8 at 4:57 PM

$PYPD This is the most boring stock in history.

1 · Reply

Nigoolas Oct. 8 at 3:30 AM

$PYPD very nice entry atm!! BEST stock ever!!

0 · Reply

Stef_DL Oct. 7 at 7:59 PM

$PYPD A temping buy whenever she dips closer to 3. I might need to step in for a little buying 😊.

0 · Reply

NVDAMillionaire Oct. 2 at 6:15 AM

0 · Reply

BenGang Oct. 1 at 3:12 PM

$PYPD

0 · Reply

WallStWireAds Sep. 30 at 4:36 PM

$PYPD https://stocktwits.com/symbol/PYPD/companycall

0 · Reply

DARKP00L Sep. 30 at 1:17 PM

$PYPD 08:50 on Sep. 30 2025 PolyPid Announces That Dr. Shmuel Sharoni Will Present Topline Phase 3 Shield II Trial Results For D-PLEX₁₀₀ At The 2025 American College Of Surgeons Clinical Congress In Chicago #tradeideas

0 · Reply

WallStWireAds Sep. 30 at 12:47 PM

$PYPD https://caplynx.io/9A7bWjm

0 · Reply

PaulWalter Sep. 29 at 9:41 PM

$PYPD Tumblweeds.

0 · Reply

WallStWireAds Sep. 21 at 7:24 PM

$PYPD https://capnotes.beehiiv.com/p/as-polypid-advances-towards-commercialization-recent-300m-m-a-activity-highlights-growing-value-of-h?li_fat_id=e2c6d6ec-41fb-4261-a410-180e10907070

1 · Reply

Project_Profit Sep. 19 at 10:46 AM

$PYPD something is cooking here. Up in the premarket... This never trades in the PM session And up after yesterday's move higher. If they would announce a partnership, $10+ here. Go ahead, do it please.

0 · Reply

WallStWireAds Sep. 17 at 12:46 PM

$PYPD https://caplynx.io/1ZusfUu

0 · Reply

sxpl Sep. 16 at 4:20 PM

$BABA $PDD $PYPD 🎯🤝

0 · Reply

WallStWireAds Sep. 16 at 12:32 PM

$PYPD https://caplynx.io/6dcuB69

1 · Reply

CARTE_BLANCHE_DEVEREAUX Sep. 5 at 5:26 AM

$PYPD Position here growing weekly.

0 · Reply

Project_Profit Sep. 3 at 2:48 PM

$PYPD Under the radar until it's on the radar $XBI

0 · Reply

WallStWireAds Sep. 3 at 12:32 PM

$PYPD https://caplynx.io/1qOjDVd

0 · Reply

Market Cap	54.69M
Revenue (ttm)	0.00
Net Income (ttm)	-29.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.32

Volume	25,100
Avg Vol	59,816
Day's Range	N/A - N/A
Shares Out	15.90M
Stochastic %K	85%
Beta	1.50
Analysts	Strong Sell
Price Target	$12.50